Related Experiment Video

Updated: Aug 5, 2026

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Attenuation of G1 checkpoint function by the non-genotoxic carcinogen phenobarbital

A J Gonzales1, J G Christensen, R J Preston

  • 1Curriculum in Toxicology, University of North Carolina, Chapel Hill 27709, USA. Andrea.Gonzales@wl.com

Carcinogenesis
|July 31, 1998
PubMed

Insights

Phenobarbital (PB) impairs the G1 cell-cycle checkpoint by reducing p53 protein, indirectly causing genetic damage. This epigenetic mechanism may explain how non-genotoxic carcinogens promote cancer development.

Area of Science:

  • Molecular Toxicology
  • Carcinogenesis Mechanisms
  • Cell Cycle Regulation

Background:

  • Non-genotoxic carcinogens induce tumors without direct DNA interaction, posing a challenge to understanding cancer initiation.
  • The accumulation of genetic alterations is a key factor in cancer development, yet the mechanisms of non-genotoxic carcinogens remain unclear.
  • Cell-cycle checkpoints are critical for preventing genetic instability by halting cell division upon DNA damage.

Purpose of the Study:

  • To investigate if phenobarbital (PB), a mitogenic non-genotoxic carcinogen, disrupts cell-cycle checkpoint controls.
  • To determine if PB indirectly leads to genetic damage accumulation by altering checkpoint function.
  • To elucidate the role of p53 in DNA damage-induced cell-cycle arrest and PB's effect on this process.

Main Methods:

  • Characterization of G1 and G2 cell-cycle checkpoint responses to bleomycin-induced DNA damage in primary mouse hepatocytes.
  • Assessment of p53 and p21WAF1 protein levels following DNA damage.
  • Utilized hepatocytes from p53-deficient mice to determine the role of p53 in checkpoint control.
  • Examined the effects of phenobarbital exposure on cell-cycle checkpoint responses and p53 protein levels.

Main Results:

  • Hepatocytes exhibited G1 and G2 cell-cycle arrest in response to DNA damage, coupled with p53 induction.
  • Phenobarbital (PB) attenuated and delayed the G1 checkpoint response, dependent on p53, without affecting the G2 checkpoint.
  • PB reduced p53 protein levels and delayed its induction following DNA damage, suggesting a role in checkpoint abrogation.
  • p21WAF1 protein levels were unchanged, indicating a specific impact on the p53-mediated G1 checkpoint.

Conclusions:

  • Altered G1 checkpoint function by phenobarbital (PB) represents an epigenetic mechanism contributing to non-genotoxic carcinogenesis.
  • PB may increase genotoxic events by impairing DNA damage detection and repair through p53 pathway modulation.
  • Disruption of cell-cycle checkpoint controls is a significant mechanistic factor in mitogenic, non-genotoxic chemical carcinogenesis.
Keywords:
Non-programmatic

More Related Videos

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants07:08

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants

Published on: March 6, 2018

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...